Full Press Release Details
« Back
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results
07/22/26 8:30 AM EDT
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 22, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, Aug. 5, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss these results.
The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260722909703/en/
Investor Contacts: Ian Estepan, 617-274-4052, iestepan@sarepta.com Ryan Wong, 617-800-4112, rwong@sarepta.com Tam Thornton, 617-803-3825, tthornton@sarepta.com
Media Contact: Tracy Sorrentino, 617-301-8566, tsorrentino@sarepta.com
Source: Sarepta Therapeutics, Inc.
This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.